0
0
August 3, 2025—New Delhi:
India is set to transform its drug approval system in a move aimed at aligning its regulatory processes with those of leading global agencies such as the US FDA and European Medicines Agency. The Central Drugs Standard Control Organisation (CDSCO), under the Ministry of Health & Family Welfare, has announced sweeping regulatory reforms designed to make drug approvals faster, more transparent, and highly reliable for both domestic and export markets.
Key Features of the Overhaul
-
Streamlined Approval Timelines:
The previous sluggish timelines for drug approvals, often stretching up to 180–270 days, have now been significantly reduced. Updated rules propose approval within 60–120 days for many categories, including orphan drugs, oncology and critical therapies, generics, and biosimilars. Fast-track review paths and pre-submission guidance windows have also been introduced for life-saving and innovative therapies. -
Digital Transformation:
The entire application, review, and approval process has moved online through the enhanced SUGAM portal, allowing for real-time tracking of applications, digital dossier submissions in eCTD format, and automated deficiency alerts. This digital initiative ensures better transparency and accountability, reducing paperwork and preventing manual delays. -
Greater Regulatory Rigour and Transparency:
The formation and operating procedures of Subject Expert Committees (SECs) are now clearly defined. These committees will play a critical role in reviewing new drug and medical device applications with stricter data integrity and global standards in mind. The overhaul follows the recommendations made by the World Health Organization after a regulatory review of India’s system last year. -
Waivers and Flexibility for Global Data:
In certain cases—especially where robust global data exists—requirements for local clinical trial data may be waived, thus expediting approvals for new drugs already tested and proven safe elsewhere. -
Enhanced Compliance for Exports:
Indian pharmaceutical manufacturers are now required to comply with Good Manufacturing Practices (GMP), particularly those set by the European Union, to ensure quality export standards and boost the reliability and international reputation of Indian medicines. -
Benefit for Multiple Stakeholders:
The updated drug approval rules are designed to benefit pharmaceutical manufacturers, biotechnology companies, academic institutions, multinational corporations, and startups—especially those focused on biosimilars, orphan drugs, gene therapies, and novel drug development.
Broader Impact and Future Direction
India’s pharmaceutical industry is a global leader, supplying about 20% of the world’s generic drugs. The new reforms are expected to further strengthen India’s reputation as the “Pharmacy of the World” by providing more efficient drug launches, ensuring higher quality standards, and enabling faster access to critical medications both domestically and internationally.
These efforts are part of a broader initiative to harmonize Indian regulations with global best practices, foster innovation, and guarantee patient safety alongside economic growth.
Disclaimer:
The above article is based on current publicly available information from official news sources and regulatory updates as of August 2025. It should not be interpreted as legal or regulatory advice. For specific compliance or implementation details, please consult the Central Drugs Standard Control Organisation (CDSCO) or authorized health regulatory bodies.
